Neuroprotective efficacy of the peroxisome proliferator-activated receptor-γ Ligand in chronic cerebral hypoperfusion

Current Neurovascular Research

Volumn 8, Issue 3, 2011, Pages 190-199

  Sayan Ozacmak, Hale ^a   Ozacmak, V Haktan ^a   Barut, Figen ^b   Jakubowska Dogru, Ewa ^c  

^a University Medical School   (Turkey)

^b Middle East Technical University ^*

^c MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Chronic cerebral hypoperfusion; S100; Spatial learning; Synaptophysin

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN S100B; ROSIGLITAZONE; ROSVEL; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELL ACTIVATION; CELL DENSITY; CHRONIC BRAIN DISEASE; CHRONIC CEREBRAL HYPOPERFUSION; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL TEST; HIPPOCAMPAL CA1 REGION; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYNAPTOGENESIS; WATER MAZE TEST; WESTERN BLOTTING;

EID: 80051496173     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720211796558087     Document Type: Article

References (57)

1. Culman J, Zhao Y, Gohlke P, Herdegen T. PPAR-.: Therapeutic target for ischemic stroke. Trends Pharmacol Sci 2007; 28: 244-249. (Pubitemid 46661003)
2. Chu K, Lee ST, Koo JS, et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res 2006; 1093: 208-218. (Pubitemid 43946402)
3. Luo Y, Yin W, Signore AP, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006; 97: 435-448.
4. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 2006; 20: 1162-1175. (Pubitemid 44943912)
5. Tureyen K, Kapadia R, Bowen KK, et al. Peroxisome proliferatoractivated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007; 101: 41-56. (Pubitemid 46426485)
6. Lee CH, Park OK, Yoo KY, et al. The role of peroxisome proliferator-activated receptor γ, and effects of its agonist, rosiglitazone, on transient cerebral ischemic damage. J Neurol Sci 2011; 300: 120-129.
7. Park SW, Yi JH, Miranpuri G, et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007; 320: 1002-1012. (Pubitemid 46294061)
8. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 2008; 1244: 164-172.
9. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferatoractivated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002; 82: 615-624. (Pubitemid 34831499)
10. Schütz B, Reimann J, Dumitrescu-Ozimek L, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005; 25: 7805-7812. (Pubitemid 41208652)
11. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199: 265-273. (Pubitemid 43928978)
12. Rodriguez-Rivera J, Denner L, Dineley KT. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral glucoregulatory status. Behav Brain Res 2011; 216: 255-261.
13. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005; 130: 685-696. (Pubitemid 39601441)
14. Berbardo A, Minghetti L. PPAR-γ agonists as regulators of microglial activation and brain inflammation. Curr Pharm Res 2006; 12: 93-109.
15. Wang CX, Ding X, Noor R, et al. Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J Cereb Blood Flow Metab 2009; 29: 1683-1694.
16. Shimazu T, Inoue I, Araki N, et al. A peroxisome proliferatoractivated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005; 36: 353-359. (Pubitemid 40170822)
17. Collino M, Aragno M, Mastrocola R, et al. Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006; 530: 70-80. (Pubitemid 43037126)
18. Pereira MP, Hurtado O, Cardenas A, et al. The nonthiazolidinedione PPARgamma agonist L-796,449 is neuroprotective in experimental stroke. J Neuropathol Exp Neurol 2005; 64: 797-805. (Pubitemid 41285813)
19. Hyong A, Jadhav V, Lee S, et al. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 2008; 1215: 218-224.
20. Sung B, Park S, Yu BP, Chung HY. Amelioration of age-related inflammation and oxidative stress by PPAR-γ activator: Suppression of NF-κB by 2,4-thiazolidinedione. Exp Gerontol 2006; 41: 590-599. (Pubitemid 43867228)
21. De La Torre JC, Fortin T, Park GA, et al. Chronic cerebrovascular insufficiency induced dementia-like deficits in aged rats. Brain Res 1992; 582: 186-195.
22. Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev 2007; 54: 162-180. (Pubitemid 46498166)
23. Liu J, Jin DZ, Xiao L, Zhu XZ. Paeoniflorin attenuates chronic cerebral hypoperfusion-induced learning dysfunction and brain damage in rats. Brain Res 2006; 1089: 162-170. (Pubitemid 43766365)
24. Guang HM, Du GH. Protections of pinocembrin on brain mitochondria contribute to cognitive improvement in chronic cerebral hypoperfused rats. Eur J Pharmacol 2006; 542: 77-83.
25. Vicente E, Degerone D, Bohn L, et al. Astroglial and cognitive effects of chronic cerebral hypoperfusion in the rat. Brain Res 2009; 1251: 204-212.
26. Liu HX, Zhang JJ, Zheng P, Zhang Y. Altered expression of MAP- 2, GAP-43, and synaptophysin in the hippocampus of rats with chronic cerebral hypoperfusion correlates with cognitive impairment. Brain Res Mol Brain Res 2005; 139: 169-177. (Pubitemid 41583599)
27. Kuang X, Du JR, Liu YX, Zhang GY, Peng HY. Postischemic administration of Z-Ligustilide ameliorates cognitive dysfunction and brain damage induced by permanent forebrain ischemia in rats. Pharmacol Biochem Behav 2008; 88: 213-221. (Pubitemid 350116248)
28. Kumaran D, Udayabanu M, Kumar M, Aneja R, Katyal A. Involvement of angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory impairment and cholinergic dysfunction in rats. Neuroscience 2008; 155: 626-639.
29. Wang J, Zhang HY, Tang XC. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion Neurosci Res 2010; 88(4): 807-15.
30. Cho KO, La HO, Cho YJ, Sung KW, Kim SY. Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion. J Neurosci Res 2006; 83: 285-291. (Pubitemid 43184392)
31. Lee JH, Park SY, Shin Y, et al. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res 2006; 1082: 182-191.
32. Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 2006; 37: 1539-1545. (Pubitemid 44305739)
33. Annahazi A, Mracsko E, Sule Z, et al. Pre-treatment and posttreatment with alpha-tocopherol attenuates hippocampal neuronal damage in experimental cerebral hypoperfusion. Eur J Pharmacol 2007; 571: 120-128. (Pubitemid 47379685)
34. Peng Y, Xu S, Chen G, Wang L, Feng Y, Wang X. l-3-nbutylphthalide improves cognitive impairment induced by chronic cerebral hypoperfusion in rats. J Pharmacol Exp Ther 2007; 321: 902-910. (Pubitemid 46762705)
35. Yasuda Y, Tateishi N, Shimoda T, Satoh S, Ogitani E, Fujita S. Relationship between S100β and GFAP expression in astrocytes during infarction and glial scar formation after mild transient ischemia. Brain Res 2004; 1021: 21-31.
36. Ohtani R, Tomimoto H, Wakita H, Kitaguchi H, Nakaji K, Takahashi R. Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. Brain Res 2007; 1135: 195-200. (Pubitemid 46176817)
37. Tanaka K, Wada-Tanaka N, Miyazaki I, Nomura M, Ogawa N. Chronic cerebral hypoperfusion induces striatal alterations due to the transient increase of NO production and the depression of glutathione content. Neurochem Res 2002; 27: 331-336. (Pubitemid 34273576)
38. He Z, Liao Y, Zheng M, Zeng FD, Guo LJ. Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Cell Mol Neurobiol 2008; 28: 613-627. (Pubitemid 351624502)
39. Chao X, Zhou J, Chen T, et al. Neuroprotective effect of osthole against acute ischemic stroke on middle cerebral ischemia occlusion in rats. Brain Res 2010; 1363: 206-11.
40. Kasparova S, Brezova V, Valko M, et al. Study of the oxidative stres in a rat model of chronic brain hypoperfusion. Neurochem Int 2005; 46: 601-611. (Pubitemid 40614863)
41. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002; 23: 655-664. (Pubitemid 35217687)
42. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008; 5: 481-489. (Pubitemid 351952487)
43. Gemma C, Stellwagen H, Fister M, et al. Rosiglitazone improves contextual fear conditioning in aged rats. Neuroreport 2004; 15: 2255-2259. (Pubitemid 39392251)
44. Bernardo A, Gasparini L, Ongini E, Minghetti L. Dynamic regulation of microglial functions by the non-steroidal antiinflammatory drug NCX 2216: implications for chronic treatments of neurodegenerative diseases. Neurobiol Dis 2006; 22: 25-32.
45. Combs C, Johnson D, Karlo C, Cannady S, Landreth G. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 2000; 20: 558-567. (Pubitemid 30225558)
46. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 2001; 39: 409-413. (Pubitemid 32907405)
47. Bialowas-Mcgoey LA, Lesicka A, Whitaker-Azmitia PM. Vitamine E S100B-mediated microglial activation in an S100Boverexpressing mouse model of pathological aging. Glia 2008; 56: 1780-1790.
48. De Jong GI, Farkas E, Stienstra CM, et al. Cerebral hypoperfusion yields capillary damage in the hippocampal CA1 area that correlates with spatial memory impairment. Neuroscience 1999; 91: 203-210. (Pubitemid 29170459)
49. Yanpallewar S, Rai S, Kumar M, Chauhan S, Acharya SB. Neuroprotective effect of Azadirachta indica on cerebral postischemic reperfusion and hypoperfusion in rats. Life Sci 2005; 76: 1325-1338.
50. Institoris A, Farkas E, Berczi S, Sule Z, Bari F. Effects of cyclooxygenase (COX) inhibition on memory impairment and hippocampal damage in the early period of cerebral hypoperfusion in rats. Eur J Pharmacol 2007; 574: 29-38. (Pubitemid 47516584)
51. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-147. (Pubitemid 27217017)
52. Sudhof TC. The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature 1995; 375: 645-646.
53. Bergmann M, Post A, Rittel I, Bechmann I, Nitsch R. Expression of synaptophysin in sprouting neurons after entorhinal lesion in the rat. Exp Brain Res 1997; 117: 80-86. (Pubitemid 27448033)
54. Wu DM, Lu J, Zheng YL, Zhou Z, Shan Q, Maa DF. Purple sweet potato color repairs D-galactose-induced spatial learning and memory impairment by regulating the expression of synaptic proteins. Neurobiol Learning Memory 2008; 90: 19-27.
55. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzhemeimer disease. J Neuropathol Exp Neurol 1997; 56: 933-944. (Pubitemid 27329114)
56. Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatr 2005; 13: 950-958. (Pubitemid 46638661)
57. Kernan WN, Inzucchi SE, Viscoli CM, et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003; 34: 1431-1436. (Pubitemid 36693512)